Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Leukemia. 2019 Apr 1;33(10):2506–2521. doi: 10.1038/s41375-019-0462-4

Figure 2: Kdm6b is required for HSC self-renewal.

Figure 2:

(a) Proportion of long-term multi-lineage reconstituted (LTMR) recipient mice at stated cell doses 16-weeks post-transplant (n=9–10 per genotype at each cell dose). (b) Frequency of long-term repopulating cells using a maximum likelihood estimate with extreme limiting dilution analysis (ELDA) software. (c) Frequency of donor-derived (CD45.2+) HSCs in BM of recipient mice 18-weeks post-transplant. (d) Peripheral blood engraftment in secondary transplants of 3.0×106 BM from LTMR primary recipient mice (n=6–8). (e) Proportion of LTMR secondary recipient mice transplanted with ControlVAV (n=6), Kdm6b-HetVAV (n=8), and Kdm6b-KOVAV (n=6) primary BM. (f) Frequency of donor-derived HSCs in BM of secondary recipient mice 18-weeks post-transplant. (g) Donor-derived peripheral blood engraftment from primary transplant of 200 HSCs from ControlVAV (n=10), Kdm6b-HetVAV (n=9), and Kdm6b-KOVAV (n=9) mice. (h) Donor-derived chimerism in blood lineages 16-weeks post-transplant of 200 HSCs. (i) Frequency of donor-derived HSCs in BM of recipient mice 18-weeks post-transplant of 200 HSCs. (j) Donor-derived peripheral blood engraftment from competitive transplant of BM from aged ControlVAV (n=3), Kdm6b-HetVAV (n=4), and Kdm6b-KOVAV (n=3) mice. (k) Donor-derived chimerism in blood lineages 16-weeks post-transplant of aged BM. (l) Frequency of donor-derived HSCs in recipient mice 18-weeks post-transplant of aged BM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Mean ± S.E.M. values are shown.